The educational design of this activity addresses the needs of allergists, clinical immunologists, and other specialist clinicians involved in the management of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) or asthma.
Upon completion of this activity, participants should be better able to:
- Compare clinically relevant inflammatory processes involved in the pathophysiology of CRSwNP and asthma
- Longitudinally evaluate patients with asthma or CRSwNP for severity of disease, control of symptoms, and treatment responses
- Discuss the biologic treatment armamentarium for CRSwNP and moderate-to-severe asthma
- Construct individualized treatment regimens for patients with CRSwNP or moderate-to-severe asthma based on symptoms, comorbidities, and shared clinical decision-making
Statement of Need
Disorders involving inflammation or tissue remodeling in the respiratory tract are responsible for significant patient morbidity, potential mortality, and tremendous burdens on health care systems.¹,² In the upper airways, chronic rhinosinusitis (CRS) is characterized by inflammation in the nasal cavity mucosa and paranasal sinuses.³ A quarter to one third of patients with CRS have associated nasal polyps (CRSwNP), which can obstruct the sinuses and nasal passages and are often associated with more severe sinonasal symptoms.⁴ In the lower airways, asthma is a chronic respiratory disease that affects more than 25 million Americans.⁵ Notably, asthma affects a large proportion of patients with CRSwNP, and the presence of nasal polyps has been associated with asthma disease severity.⁶ An outsized segment of asthma-related morbidity and mortality is borne by the 5% to 15% of patients who have more severe forms of the disease.⁷ Research has uncovered pathophysiologic and phenotypic associations between diseases of the upper and lower airways, such as CRS and asthma, leading to the development of novel therapies for these disorders.⁸ A number of biologic medications are now available to treat certain cohorts of patients with moderate-to-severe asthma, and recently the first biologic therapy for treatment of CRSwNP has been approved by the US Food and Drug Administration (FDA).⁹,¹⁰ Clinical immunologists, allergists, and other specialists who manage patients with CRSwNP and asthma will be increasingly tasked with personalizing the choice of treatment based on the severity of symptoms, presence of comorbidities, and disease phenotypes and endotypes. Thus, clinicians must be vigilant about staying current on the latest clinical data, treatment recommendations, and new approvals from the FDA. During this Case-in-Point™ educational program, a panel of expert faculty will guide learners through unique clinical case scenarios, sharing relevant guideline recommendations, published data, and clinical insights before a brief question-and-answer session concludes each case discussion. Program attendees will find this interactive session informative and engaging, as it combines evidence-based management strategies and real-world experience into actionable best-practice recommendations that can shape therapeutic decision-making.
- Lang DM. Allergy Asthma Proc. 2015;36(6):418-424.
- Bhattacharyya N, et al. Laryngoscope. 2019;129(9):1969-1975.
- Orlandi RR, et al. Int Forum Allergy Rhinol. 2016;6(suppl 1):S22-S209.
- Stevens WW, et al. J Allergy Clin Immunol Pract. 2016;4(4):565-572.
- Centers for Disease Control and Prevention (CDC). Asthma Facts: CDC’s National Asthma Control Program Grantees. Atlanta, GA: US Department of Health and Human Services. 2013.
- Fokkens WJ, et al. Allergy. 2019;74(12):2312-2319.
- Chung KF, et al. Eur Respir J. 2014;43(2):343-373.
- Rosati MG, Peters AT. Am J Rhinol Allergy. 2016;30(1):44-47.
- Assaf SM, Hanania NA. Curr Opin Allergy Clin Immunol. 2019;19(4):379-386.
- Laidlaw TM, Buchheit KM. Ann Allergy Asthma Immunol. 2019. [Epub ahead of print].